Outcomes of Treatment for Melanoma Brain Metastases

<table class="table-group" id="tab4"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">BRAF mutations</td><td class="align_center">Number of patients</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">V600K</td><td class="align_center">1 (12.5%)</td></tr><tr><td class="align_left">V600M</td><td class="align_center">1 (12.5%)</td></tr><tr><td class="align_left">V600E</td><td class="align_center">6 (75%)</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>BRAF mutations in melanoma patients.</div>

Journal of Skin Cancer

tab4

Table 4

Table 4: Outcomes of Treatment for Melanoma Brain Metastases 